Bruker Corporation (NASDAQ:BRKR) Receives $50.38 Average PT from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have been given a consensus recommendation of “Hold” by the fifteen research firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, five have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $50.3846.

A number of analysts have issued reports on the stock. UBS Group reiterated a “neutral” rating and set a $49.00 price target on shares of Bruker in a research note on Friday, February 13th. Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a research note on Wednesday, December 10th. Rothschild & Co Redburn set a $60.00 target price on shares of Bruker in a report on Thursday, November 20th. Bank of America boosted their price target on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Barclays cut their price target on Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 13th.

Bruker Stock Down 2.2%

Shares of NASDAQ BRKR opened at $40.11 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. The business’s 50 day moving average is $45.64 and its two-hundred day moving average is $40.85. Bruker has a 52-week low of $28.53 and a 52-week high of $56.22. The firm has a market cap of $6.09 billion, a price-to-earnings ratio of -267.40, a PEG ratio of 2.40 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). The firm had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts predict that Bruker will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be paid a $0.05 dividend. The ex-dividend date is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s payout ratio is currently -133.33%.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 7,000 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $55.00, for a total value of $385,000.00. Following the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. This represents a 5.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 27.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bruker

Institutional investors and hedge funds have recently modified their holdings of the company. Sector Gamma AS lifted its stake in shares of Bruker by 28.0% in the 3rd quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock worth $8,152,000 after acquiring an additional 54,939 shares during the period. State of New Jersey Common Pension Fund D raised its holdings in Bruker by 39.0% during the second quarter. State of New Jersey Common Pension Fund D now owns 51,828 shares of the medical research company’s stock worth $2,135,000 after purchasing an additional 14,547 shares in the last quarter. M&G PLC raised its holdings in Bruker by 233.0% during the third quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock worth $35,079,000 after purchasing an additional 766,992 shares in the last quarter. Buckhead Capital Management LLC lifted its position in Bruker by 74.2% in the second quarter. Buckhead Capital Management LLC now owns 59,348 shares of the medical research company’s stock valued at $2,445,000 after purchasing an additional 25,288 shares during the period. Finally, New York State Common Retirement Fund boosted its holdings in Bruker by 52.5% in the 3rd quarter. New York State Common Retirement Fund now owns 370,797 shares of the medical research company’s stock valued at $12,047,000 after purchasing an additional 127,698 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.